| General information | Literature | Expression | Regulation | Mutation | Interaction |
Basic Information | |
|---|---|
Gene ID | 7433 |
Name | VIPR1 |
Synonymous | HVR1|II|PACAP-R-2|PACAP-R2|RDC1|V1RG|VAPC1|VIP-R-1|VIPR|VIRG|VPAC1|VPAC1R|VPCAP1R;vasoactive intestinal peptide receptor 1;VIPR1;vasoactive intestinal peptide receptor 1 |
Definition | PACAP type II receptor|VIP and PACAP receptor 1|VIP receptor, type I|pituitary adenylate cyclase activating polypeptide receptor, type II|vasoactive intestinal polypeptide receptor 1 |
Position | 3p22 |
Gene type | protein-coding |
Cancer type | Abstract |
| central primitive neuroectodermal Tumors?;Neurological | Vasoactive intestinal peptide (VIP) is a neuromodulator and growth regulator in the developing nervous system. We analyzed 10 primitive neuroectodermal tumor (PNET) cell lines, 29 central PNET (cPNET) and 17 tumors of the Ewing's sarcoma/peripheral PNET family (ESFT) using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern hybridization. Each of the 10 cell lines and 86.2% of cPNET expressed mRNA for VIP receptor 1 (VIPR1) compared to 52.9% of ESFT. VIPR2 was expressed in 75.8% of cPNET, in 28.6% of ESFT and in ALL 10 celllines. cPNET demonstrated high-affinity binding of 125I-VIP on quantitative autoradiography and in competitive binding assays. VIP inhibited tumor cell proliferation in a dose-dependent manner in 5 of 7 PNET cell lines. We conclude that VIPR1 and VIPR2 are highly expressed in cPNET and demonstrate that VIP is agrowth modulator in these tumors. |